STOCK TITAN

AIM ImmunoTech Inc - AIM STOCK NEWS

Welcome to our dedicated news page for AIM ImmunoTech (Ticker: AIM), a resource for investors and traders seeking the latest updates and insights on AIM ImmunoTech.

Our selection of high-quality news articles is accompanied by an expert summary from Rhea-AI, detailing the impact and sentiment surrounding the news at the time of release, providing a deeper understanding of how each news could potentially affect AIM ImmunoTech's stock performance. The page also features a concise end-of-day stock performance summary, highlighting the actual market reaction to each news event. The list of tags makes it easy to classify and navigate through different types of news, whether you're interested in earnings reports, stock offerings, stock splits, clinical trials, fda approvals, dividends or buybacks.

Designed with both novice traders and seasoned investors in mind, our page aims to simplify the complex world of stock market news. By combining real-time updates, Rhea-AI's analytical insights, and historical stock performance data, we provide a holistic view of AIM ImmunoTech's position in the market.

Rhea-AI Summary
AIM ImmunoTech Inc. highlights progress in Ampligen clinical development programs for various indications, including Post-COVID conditions, pancreatic cancer, and ovarian cancer. Recent accomplishments include positive results in the AMP-518 study and the DURIPANC study. The company emphasizes building upon scientific success and anticipates significant value for stockholders. Upcoming milestones include interim results for advanced recurrent ovarian cancer and final dataset for Post-COVID conditions in Q1 and Q2 2024, respectively.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
AIM ImmunoTech Inc. announced the dosing of the first subject in a Phase 1b/2 clinical trial combining Ampligen with Imfinzi for late-stage pancreatic cancer treatment. The study is expected to be completed within six months.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
2.5%
Tags
clinical trial
-
Rhea-AI Summary
AIM ImmunoTech Inc. announces positive topline results from Phase 2 study of Ampligen in treating Post-COVID fatigue. Initial analysis shows lower fatigue levels in Ampligen group at multiple time points. The Six-Minute Walk Test also reveals a higher impact of Ampligen on distance traveled compared to placebo. Safety results indicate Ampligen is generally well-tolerated with no severe adverse events.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-13.64%
Tags
clinical trial covid-19
Rhea-AI Summary
AIM ImmunoTech Inc. has received authorization from the Erasmus Medical Center Ethics Committee to open a European site for the ongoing Phase 2 study of Ampligen as a therapy for locally advanced pancreatic cancer. The approval is a significant step towards enrolling subjects in the European arm of the clinical trial. The study aims to compare the efficacy of Ampligen versus a no treatment control group following FOLFIRINOX for subjects with locally advanced pancreatic adenocarcinoma. Subject enrollment is expected in Q1 2024, with approximately 90 subjects to be enrolled in the United States and Europe.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-6.98%
Tags
clinical trial
-
Rhea-AI Summary
AIM ImmunoTech Inc. announced the enrollment of the first subject in a Phase 1b/2 clinical trial combining Ampligen with AstraZeneca’s Imfinzi for late-stage pancreatic cancer treatment. Positive clinical data could make AIM an attractive buyout target. AIM secured a U.S. patent for Ampligen's use in combination therapy. The trial aims to determine safety and clinical benefit rates of the combination therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
clinical trial
-
Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announced the opening of enrollment in a Phase 1b/2 clinical trial at Erasmus Medical Center in Rotterdam, Netherlands, for the treatment of pancreatic cancer. The trial will combine AIM's Ampligen with AstraZeneca's Imfinzi, aiming to determine the safety and clinical benefit rate of the combination therapy.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
0.92%
Tags
clinical trial
Rhea-AI Summary
AIM ImmunoTech Inc. (AIM) announces the election of all four directors at the 2023 Annual Meeting of Stockholders. The company expresses gratitude to shareholders and emphasizes commitment to delivering life-saving treatments and creating shareholder value.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
-
Rhea-AI Summary
Court Found that Several AIM Advance Notice Bylaws Are Invalid. The Delaware Court of Chancery ruled in favor of the Kellner Group, finding four separate advance notice bylaw provisions adopted by AIM Immunotech Inc. to be invalid. However, the Court also found that Mr. Kellner's notice of nominations did not comply with certain remaining advance notice provisions. AIM announced that it will disregard the Kellner Group's nominations, and any proxies voted in favor of the Kellner Group nominees will not be recognized or tabulated at the Annual Meeting.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-- %
Tags
none
-
Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) announced the Delaware Court of Chancery ruled against the Activist Group's nomination notice, finding it invalid under the Company's Bylaws. The Court upheld the Board's decision to reject the notice due to omissions and misleading information. AIM will reconvene its 2023 Annual Meeting and adjourn until January 5th, disregarding any proxies submitted by the Activist Group. The Board urges shareholders to vote for all four Company Directors on the WHITE Proxy Card.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
-8.33%
Tags
none
Rhea-AI Summary
AIM ImmunoTech Inc. (NYSE American: AIM) will convene its 2023 Annual Meeting of Stockholders on December 1st, adjourning until December 29th to await a ruling from the Delaware Court of Chancery regarding litigation brought against the Company and its directors by an Activist Group seeking to nominate three candidates for election to AIM's Board of Directors. The Board has determined the Activist Group's nomination notice as invalid and will disregard any proxies or votes cast for the individuals on the Activist Group's proxy card unless the litigation results in a finding that the Notice is valid. The record date for determining shareholders eligible to vote at the 2023 Annual Meeting remains October 2, 2023.
Rhea-AI Impact
Rhea-AI Sentiment
End-of-Day
6.82%
Tags
none
AIM ImmunoTech Inc

NYSE:AIM

AIM Rankings

AIM Stock Data

19.57M
44.60M
8.69%
8.52%
0.89%
Biological Product (except Diagnostic) Manufacturing
Manufacturing
Link
US
Ocala

About AIM

aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as